Hogan Lovells Publications
What’s next for representative actions in the EU and UK? Hogan Lovells speaks at BIICL
25 February 2021
Adeela Khan
AssociateLondon
Email [email protected]hoganlovells.com
Phone +44 20 7296 2862
Fax +44 20 7296 2001
LanguagesEnglish, Urdu
Practice groupLitigation, Arbitration, and Employment
As part of the firm's market-leading product liability practice, Adeela Khan advises clients on commercial litigation and regulatory issues.
She has experience in acting for life science clients in both litigation and arbitration involving allegations of regulatory and contractual breaches. She also advises major manufacturers on EU and UK product regulations. This involves helping clients ensure their products comply with relevant safety legislation, assisting them in their conversations with regulators, and managing potential product safety risks.
Adeela maintains a varied pro bono practice and has assisted with applications for criminal injuries compensation, and advised on the establishment and operations of a charitable incorporated organisation.
As a trainee, Adeela spent six months in our Paris office, where she gained experience in international arbitration. Prior to moving to the UK, she lived in Pakistan where she gained work experience at a corporate law firm.
Education and admissions
Education
LPC, BPP University Law School, 2016
GDL, BPP University Law School, 2014
B.A. (Hons), University of Oxford, 2013
Bar admissions and qualifications
Solicitor, England and Wales
Representative experience
Defending clients on product liability claims and group actions threatened by consumers alleging defects in products.
Advising automotive companies on regulatory matters.
Representing life science clients in coroner's inquests following the death of patients alleged to be linked to products.
Assisting with the defence of a life science client in potential arbitration alleging regulatory and contractual breaches.
Assisting a biotech client with advice on a claim against a CRO regarding the conduct of a large-scale multi-centre Phase III clinical trial.
